back print

daily work against drug use in sport


Doping has become more and more a topic in all sports. In 2003, the AIBA Medical Commission and AIBA Headquarters worked hard to implement the World Anti-Doping Code in the AIBA Anti-Doping Rules. Since then, AIBA remains in daily contact with the World Anti-Doping Agency (WADA) and is always alerted to new substances and changes.

AIBA Compliance to the New World Anti-Doping Code 2009

Our Anti-Doping organisation

AIBA shall principally act under the AIBA's Anti-Doping Rules by the following person(s) or bodies:

The AIBA Anti-Doping Department is under the responsibility of the AIBA Sport Department.

The Anti-Doping Sub-Commission is chaired by Dr. Robin Goodfellow.

Sub-Commission: .


Executive Committee

The Executive Committee has a duty to the AIBA Congress to oversee and supervise the activities of AIBA in accordance with its Objects. One of these Objects is to promote a true AIBA spirit.

The Executive Committee has specific powers under the Article of Association. The Executive Committee has the power to:

  • approve, reject or amend the AIBA's Anti-Doping Rules,
  • pronounce provisional suspensions,
  • appoint an AIBA Doping Hearing Panel and an AIBA TUE Panel,
  • reduce the period of Ineligibility in an individual case where the Athlete has provided substantial assistance to AIBA which results in AIBA discovering or establishing an anti-doping rule violation by another person involving possession under specific articles,
  • withhold some or all funding or other non-financial support to National Federations that are not in compliance with the AIBA's Anti-Doping Rules,
  • request National Federations to reimburse AIBA for all costs related to a violation of the AIBA's Anti-Doping Rules committed by a boxer or other person affiliated with that National Federation,
  • take additional disciplinary action against National Federations with respect to recognition, the eligibility of its officials and boxers to participate in International Events and fines based on the Rules,
  • confirm suspension.

Medical Commission

The Medical Commission is appointed as Commission of the Executive Committee to make recommendations in the first place to the Executive Committee with regard to the physical well being of Athletes and collect information on medical matters relating to boxing.  


  • consists of its Chairman, or Vice-Chairman, Secretary and Members; the AIBA Medical Commission is built around 14 core Members ( all of whom shall be qualified Doctors of Medicine) who shall meet at least once a year,
  • report to the Executive Committee on its activities before each Executive Committee meeting,
  • communicate with AIBA Headquarters on all anti-doping and related matters through the AIBA Anti-Doping Department.

Doping Control Sub-Commission

The Doping Control Sub-Commission (DCSC) is appointed as a Sub-Commission of the AIBA Medical Commission and has responsibility for the following further specific tasks under these AIBA’s Anti-Doping Rules:

  • publishing the AIBA’s Anti-Doping Rules and amendments to the Rules, as often as may be required. The AIBA’s Anti-Doping Rules shall comprise, either directly or by reference, the following documents issued by WADA: the Prohibited List, the International Standard for Testing, the International Standard for Laboratories and the International Standard for Therapeutic Use Exemptions together with any additions to such documents, or further procedures or guidelines, that may be deemed necessary to comply with these AIBA’s Anti-Doping Rules or otherwise pursue the AIBA’s Anti-Doping Programme. The AIBA’s Anti-Doping Rules, and any proposed amendment to them, unless otherwise stated in the Rules, must be approved by the Executive Committee. Upon giving its approval, the Executive Committee shall fix a date on which the AIBA’s Anti-Doping Rules, or any proposed amendment to them, shall take effect. The AIBA Headquarters shall notify the National Federations of this date and shall publish the AIBA’s Anti-Doping Rules, and any proposed amendment to them, on the AIBA’s website,
  • advising the AIBA Medical Commission on amendments to these AIBA’s Anti-Doping Rules as may be necessary from time to time,
  • planning, implementing and monitoring anti-doping information and anti-doping education programmes,
  • advising on sport-specific information in regard to the specificity of the sport and the type of performance enhancing substances,
  • reviewing the WADA Prohibited List in relation to specific knowledge about all disciplines of boxing,

The Doping Control Sub-Commission reports to the Chair of the AIBA Medical Commission Committee on its activities before each Executive Committee meeting. It shall communicate with AIBA Headquarters on all anti-doping and related matters through the AIBA Anti-Doping Department. The report will be part of the Medical Commission report.



The AIBA TUE Panel has been appointed by the Executive Committee on recommendation of the AIBA Medical Commission and considers requests for TUEs. Upon AIBA’s receipt of a TUE request, the Chair of the TUE Panel shall appoint three members of the TUE Panel (which may include the Chair) to consider such request. The TUE Panel member(s) so designated will promptly evaluate such request in accordance with the International Standard for TUEs and render a decision on such request, which will be the final decision of AIBA.


AIBA Hearing Panel

The AIBA Hearing Panel is appointed by the Executive Committee. The Panel consists of a Chair, the AIBA DCSC chairman and four other experts with experience in anti-doping. The Chair will be a lawyer. 

When sitting in judgment of a doping case, no panel member from the same continent shall sit in the decision panel:

The AIBA Hearing Panel:  

  • must adjudicate when it appears, following the Results Management process described in Article 7 of the AIBA Anti-Doping Rules that these AIBA’s Anti-Doping Rules have been violated in connection with AIBA Testing or Testing at an International Event,
  • must consist of a Chair, the AIBA DCSC Chairman and three other members to hear each case. At least one appointed member shall be a lawyer and appointed members shall have had no prior involvement with the case and shall not have the same nationality as the Athlete or other Person alleged to have violated these AIBA’s Anti-Doping Rules,
  • upon request from AIBA – shall conduct a hearing at the responsibility and at the expense of the National Federation if the completion of the national hearing is delayed beyond three months.


The AIBA Anti-Doping Administrator is the head of AIBA’s Anti-Doping Department. He shall have responsibility for implementing the anti-doping programme which has been established by the Doping Control Sub-Commission. He reports to the Medical Commission and to the Doping Control Sub-Commission in this regard at least twice a year at the time of the Medical Commission and Doping Control Sub-Commission meetings and, more regularly, if called upon to do so.

The AIBA Anti-Doping Administrator has responsibility for the day to day administration of doping cases arising under there AIBA’s Anti-Doping Rules. In particular, the AIBA Anti-Doping Administrator is  the Person responsible, where applicable, for conducting the results management process in accordance with the AIBA’s Anti-Doping Rules.

Where doping control is the responsibility of the AIBA Anti-Doping Administrator under Article 7.1of the AIBA Anti-Doping Rules, the Athlete shall be suspended by the AIBA Anti-Doping Administrator after consultation of the AIBA DCSC Chair.

The AIBA Anti-Doping Administrator may at any time in the course of his work seek an advisory opinion from the ChairPerson of the Medical Commission and the ChairPerson of the Doping Control Sub-Commission, from the AIBA TUE Panel, from the AIBA Doping Hearing Panel or from such other Person as he considers to be appropriate.

The AIBA Anti-Doping Administrator shall participate at any international competition or meeting needed for the administration of doping cases and the fight against doping.